on presenting characteristics over the telestroke network. 17 In our current study, we assessed the validity of our TeleStroke Mimic (TM) score across 3 distinct US and European telestroke networks.
Methods

Patient Population
We report data from 3 distinct US and European telestroke networks, namely University of Utah Telestroke Program (UTS) in Salt Lake City, Utah; Augusta University, formerly Georgia Regents University, Telestroke Network (GRU) in Augusta, Georgia; and the TeleMedical Project for Integrative Stroke Care (TEMPiS) in Bavaria, Germany. Data were collected from the clinical documentation captured in the telestroke registry or case log utilized at each center. Each center uses a different method for data collection, so personnel at each center abstracted the pertinent deidentified variables from their database and shared them with the study team where they were combined for statistical analysis. We requested the data on the variables that we previously found to be significantly associated with SM and used to develop the TM score. These variables were age in years at time of stroke; medical history at the time of consult of atrial fibrillation, hypertension, or seizure disorder; and the binary variables of an initial, telestroke-performed National Institutes of Health Stroke Scale (NIHSS) score of >14 or ≤14 and the presence or absence of facial weakness at presentation. Patients with missing variables from GRU were excluded from the analysis, whereas at UTS and TEMPiS, if history of atrial fibrillation, hypertension, or seizure was not recorded, it was considered not present. The data that support the findings of this study are available from the corresponding author on reasonable request.
The 3 centers included in the analysis each provide 24-hour coverage of telestroke for community hospitals in their geographic region using real-time videoconferencing and teleradiology. During the study period, UTS had 23 regional spoke hospitals in its network providing care in the state of Utah and the neighboring states of Nevada, Idaho, Wyoming, and Colorado (https://healthcare.utah.edu/neurosciences/neurology/telestroke-program.php). GRU extends stroke care across the large state of Georgia and has 24 regional hospitals in its network (http://www.augusta.edu/μg/neurology/specialties/stroke/ telestroke.php). TEMPiS consists of a network of 2 specialized stroke centers (Munich-Harlaching and the University of Regensburg) and 15 regional hospitals in eastern Bavaria/Germany, detailed descriptions have been published previously. 18 Ethics approval was obtained by each center before sharing the data, and institutional review board waived the need for patient consent.
Definitions
Cerebrovascular Disease
Patients diagnosed with acute ischemic stroke, subacute ischemic stroke, and transient ischemic attack were grouped together as cerebrovascular disease. There were no cases of telestroke consultation for intracerebral hemorrhage because of exclusion by study criteria.
Stroke Mimics
This group consisted of patients who were not diagnosed with cerebrovascular disease but had a telestroke consult. Diagnoses of patients in this group included migraine/headache, seizure, encephalopathy, conversion disorder, etc.
TeleStroke Evaluation, Workflow, and Diagnostic Classification
The typical workflow associated with telestroke consultation has been described in our prior article. Briefly, during telestroke consultation, the stroke expert has the opportunity to review imaging, examine the patient with the help of a bedside assistant, perform an NIHSS, and discuss the details of the presentation and symptoms with the patient and any family or witnesses present at the bedside. At the conclusion of the teleconsultation, the stroke expert assigns a diagnosis based on review of all the available clinical and imaging data. For these analyses, diagnoses were classified as either ischemic cerebrovascular disease (iCVD) if they were acute or subacute ischemic stroke or transient ischemic attack; otherwise, they were assigned a diagnosis of stroke mimic (SM). Hemorrhagic strokes (ie, subarachnoid and intracerebral hemorrhages) were excluded from the study.
Statistical Analysis
The TM score, which we previously derived and validated in our Partners National Telestroke Network, is listed below. TM score=(age in years multiplied by 0.2) points+6 points (if history of atrial fibrillation+3 points (if history of hypertension)+9 points (if facial weakness present)+5 points (if NIHSS >14)−6 points (if history of seizure disorder).
Based on an inflection point in the NIHSS distribution, a categorical cutpoint of NIHSS >14 was chosen to construct a binary variable in our derivative analysis.
17 Figure 1 depicts the simple nomogram that was developed for ease of use by physicians during telestroke consult. In our current study, categorical variables were analyzed by χ 2 test and continuous variables by independent sample t test or Wilcoxon rank-sum test to compare mean or median differences. The TM score for any individual patient was determined by summing the points assigned for each factor present. Model discrimination was assessed by the receiver-operating characteristic area under the curve, which is equivalent to the C statistic. 19 All statistical analyses were performed using SPSS v. 20.
Results
The characteristics between patients with SM and iCVD were compared at each site separately and then as a pooled cohort. Although a few variables were not significantly different in univariate testing at the site level, likely because of small sample size, they were all significant in the pooled validation cohort. The results for each site are reported individually as follows:
UTS provided data on 187 telestroke consultations, of which 44% were SMs. Patients with SM had significantly lower NIHSS, less often had NIHSS of >14, less often had facial weakness on presentation, and more often had a history of seizure; SMs were more often, but not significantly, younger and with less atrial fibrillation ( Table 1) .
TEMPiS provided data on 1024 telestroke consultations, of which 24% were SMs. Patients with SM were significantly younger, had lower NIHSS at presentation, less often had NIHSS >14, less often had facial weakness, and less often had a history of atrial fibrillation or hypertension with more often a history of seizure (Table 2) .
GRU provided data on 719 telestroke consultations, of which 41% were SMs. Patients with SM were significantly younger, had lower NIHSS at presentation, less often had NIHSS >14, less often had facial weakness, and less often had a history of atrial fibrillation or hypertension with more often a history of seizure (Table 3) .
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When the 3 sites were combined into a pooled validation cohort, all 6 variables included in the TM score were significantly different between patients with SM and iCVD (Table 4) . Our external validation cohort performed well on receiver-operating characteristic curve analysis with an area under the curve of 0.72 (95% confidence interval, 0.70-0.73; P<0.001). When analyzed separately for each network, areas under the curve were similar across the networks (Figures I through III in the online-only Data Supplement). These data confirm that the prediction rule generates an acceptable degree of classification in this population (Figure 2 ). Of note, the rate of SMs was lower in the TEMPiS cohort than the US sites (24.3% versus 42%; P=0.005).
Discussion
Using 3 distinct US and European telestroke networks, we have shown that a model based on the 6 factors that were associated with SMs allows us to differentiate between SMs and patients with true iCVD on telestroke consults with reasonable model performance. The described predictive model represents a real-time clinical decision-making aid to prompt consideration of the possibility of an SM and is not intended as a diagnostic classification tool.
To our knowledge, this is the largest cohort study to date evaluating SMs in both a national and international telestroke network sample. Rates of SMs presenting at the spokes of our 2 US-based telestroke networks (UTS and GRU) were higher than those reported for patients presenting directly to stroke centers in the United States, possibly because community referral hospitals are less experienced or are encouraged to call for consultation more frequently. The rate in TEMPiS was lower and at the upper end of the reported range of 5% to 25% SM. In one of the earliest studies on patients with SM by Harbison et al, 20 the SM rate was 27% in a series of 487 consecutive patients who were directly admitted to a stroke service during a 6-month period. Hand et al 9 reported that among 350 consecutive patients with focal brain dysfunction of sudden onset presenting to an urban teaching hospital, 31% were SMs. A recent series from a single stroke center found that 27% of patients referred from the emergency department as a stroke code did not have a cerebrovascular disorder, and the proportion of inpatient SMs among patients admitted for suspected cerebrovascular disease was even higher. 21 The lower rate of SMs in TEMPiS may be because their practice model is different from that in most US telestroke programs, in that patients consulted in TEMPiS generally all remain at the referring hospital. Additionally, despite a smaller network of only 15 hospitals, TEMPiS has higher consult volumes and dedicates one quarter of its budget to site education. This combination of factors may result in better recognition and exclusion of likely SMs upfront by the referring providers. Although the true cause of this difference is uncertain, it is reassuring that the score still performs well even in a scenario where the incidence of the condition is dramatically lower.
Several clinical factors that predict the presence of SM have been previously identified, including that patients with SMs are younger and have fewer vascular risk factors. 9, 10, 12, 15, 22 The current confirmed this as well while being one of the first to explore these factors in patients managed during telestroke consultations nationally and internationally. They were also observed to have less facial droop and a lower initial median NIHSS. Chang et al 23 also reported a lower frequency of focal weakness and a lower median NIHSS in patients with SM. Commensurate with the available literature, the SM group had a significantly higher percentage of patients with a medical history of seizure. 9, 12, 14 Recognizing patient characteristics that differentiate patients with iCVD from patients with SM can be extremely useful when evaluating patients during telestroke consults. One interesting finding from our data is the association between the absence of facial weakness and an SM diagnosis. This suggests that patients with conditions that mimic stroke often do not have facial weakness, and this may be an important feature to focus on during the evaluation of potential SMs during telestroke evaluation. Still, across the cohort, 17% of patients with SM had facial weakness and thus its presence should not be construed as diagnostic of iCVD. Similarly, the presence of a seizure disorder raises the likelihood that the current symptoms may be because of seizures with a Todd paralysis; however, a careful evaluation is still required because some of these patients will have a new iCVD event. Advanced imaging may be useful in these patients to exclude ischemia, although in the acute tPA window, this may be impractical, particularly for a community regional hospital.
As telestroke is rapidly being adopted, 4 neurologists can anticipate an increased incidence of SM in the population of telestroke consultations. It may be beneficial to have a simple prediction rule, which can be used to heighten awareness. However, a major issue with prediction rules is that physicians have found prediction rules difficult to implement in real-time use. 24 The prediction rule presented herein is based on the information easily available at the time of the initial emergency department evaluation, uses variables that are intuitive and biologically plausible, and is calculated in a straightforward manner. We have also produced a nomogram, which could be printed and carried on a pocket-sized card and used to estimate the likelihood of a patient being an SM. 
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There are inherent limitations in the interpretations of the current study design. First, it is a retrospective analysis of prospectively collected datasets. There may be incomplete data capture and inaccuracies in data abstraction, and risk factors may have been abstracted with some variability across sites. Because we only analyzed clinical factors previously identified as predictive of SM, we may have missed some important patient characteristics in this data set, which could be associated with SMs and add discriminating power to our prediction rule. Random measurement error and misclassification can lead to dilution bias and underestimation of the effects of the tested risk factors. However, the factors in our prediction rule were routinely recorded and are relatively unlikely to be systematically influenced by the consulting neurologist judgment; however, they might have been omitted if a careful history was not obtained or was not available at the time of consultation. The stroke neurologist's clinical diagnosis (iCVD versus SM) is the reference standard used in these analyses to classify patients. We had no alternative method available to further validate this diagnosis because only a fraction of patients are transferred to the hub hospital post-consultation for further evaluation or definitive imaging. Last, it is possible that SMs evaluated in person might have different characteristics than those seen over telestroke where a referring physician has already applied some judgment as to the likelihood of iCVD by initiating the consultation. Therefore, our findings should also be replicated in traditional, in-person environments before being applied in these scenarios. An ongoing analysis is exploring the predictive capacity of our TM score in in-person evaluation.
In conclusion, we think that as telestroke consultation expands, increasing number of patients with SM will be evaluated. These patients with SM differ substantially from their counterpart patients with iCVD in their vascular risk profiles and other characteristics. Decision-making support tools based on predictive models, like the TM score we developed and have now externally validated at 3 distinct US and European telestroke networks, may help clinicians consider alternative diagnosis and potentially help identify SMs in a setting with telemedicine support.
